Weight, fat area, running and blood markers
The outcome determines the comparison. These studies cannot supply a league table of interchangeable metabolic effects.
The outcome ledger
The endpoint earns the first column in my comparison. AOD-9604, tesamorelin and MOTS-c have been studied in different populations, with different instruments and very different consequences for a treatment claim.
| Measurement | Who or what was studied | Result and boundary |
|---|---|---|
| Body weight | Adults with obesity in the AOD-9604 programme | The human programme failed to establish statistically significant weight loss versus placebo; tolerability resembled placebo. |
| Visceral-fat area | 50 adults with HIV on antiretroviral treatment | Tesamorelin’s 6-month trial found a treatment effect of -42 cm² versus placebo. This is an internal-fat area measurement. |
| Sustained visceral-fat reduction | Adults with HIV-associated abdominal fat accumulation | The 52-week programme reported an 18% reduction during treatment and reaccumulation after discontinuation. |
| Running, grip and gait | Mice, including aged animals | Extra MOTS-c improved physical performance in mice. Human treatment benefit remains unestablished. |
| Circulating peptide and illness risk | 94 chronic hemodialysis patients | MOTS-c blood levels were associated with a composite of all-cause mortality and nonfatal cardiovascular events. The cohort received no MOTS-c intervention. |
The square centimetres and the percentage above come from different tesamorelin studies, using different comparisons. They cannot be added together or exchanged for a kilogram figure. Leaving the units visibly awkward is preferable to making the compounds look conveniently comparable.
Growth-hormone signalling compared
AOD-9604 copies an altered portion of growth hormone while avoiding the growth hormone receptor. Its cell and rodent metabolic research explored the fragment’s fat-related actions. Tesamorelin instead stimulates the pituitary to release growth hormone; a short study in healthy men measured hormone pulses and IGF-1. The biological approaches differ before an outcome is even measured.
MOTS-c comes from mitochondrial DNA. Its cell-signalling and animal literature concerns fuel handling, stress responses and physical performance. A shared connection to fat or glucose leaves these mechanisms—and the evidence supporting them—quite distinct.
Approval and future trials
Tesamorelin’s FDA approval covers excess abdominal fat in adults with HIV-associated lipodystrophy. AOD-9604 and MOTS-c have no FDA-approved treatment use. None of these compounds has approval for general weight loss, and all three are prohibited in sport.
My judgment is most favourable toward the demonstrated tesamorelin effect in the population actually tested. Its durability and longer-term safety still matter. For AOD-9604, the failed human weight endpoint is the major obstacle; for MOTS-c, the crucial human intervention evidence has yet to arrive.
The AOD-9604, tesamorelin and MOTS-c pages follow those different histories. This comparison makes no treatment selection for an individual reader.